BioPharma Resources

Drug Trial Radar · NCT04557462

A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy

A Multicenter Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan in Adult Participants With Primary IgA Nephropathy Who Have Completed Study CLNP023X2203 or CLNP023A2301

Last checked: Nov 19, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

540

Planned (sponsor's estimate)

Start

Sep 20, 2021

Primary completion

Dec 4, 2030

Study completion Dec 4, 2030

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Sep 21, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the long-term safety and tolerability, of open label iptacopan in primary IgA nephropathy participants who have completed either the CLNP023X2203 or CLNP023A2301 clinical trials. The open-label design of the current study is appropriate to provide study participants the opportunity to receive treatment with iptacopan until marketing authorizations are received and the drug product becomes commercially available while enabling collection of long-term safety and tolerability data for the investigational drug. Furthermore efficacy assessments conducted every 6 months will afford the opportunity to evaluate the clinical effects of iptacopan on long-term disease progression.

Conditions

  • Primary IgA Nephropathy

Interventions

  • LNP023Drug

    Capsule 200 mg (b.i.d.) taken orally twice a day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number and percentage of participants with serious adverse eventTime frame: Date of first administration of (Day 1) to 7 days after the date of the last actual administration of study treatment
  2. Number and percentage of participants with adverse eventTime frame: Date of first administration of study treatment (Day 1) to 7 days after the date of the last actual administration of study treatment
  3. Number and percentage of participants with adverse events of special interestTime frame: Date of first administration of study treatment (Day 1) to 7 days after the date of the last actual adminstration of study treatment
  4. Number and percentage of participants with abnormalities in vital signsTime frame: Date of first administration of study treatment (Day 1) to 7 days after the date of the last actual administration of study treatment
  5. Number and percentage of participants with abnormalities in ECGTime frame: Date of first administration of study treatment (Day 1) to 7 days after the date of the last actual administration of study treatment
  6. Number and percentage of participants with abnormalities in clinical laboratory evaluationsTime frame: Date of first administration of study treatment (Day 1) to 7 days after the date of the last actual administration of study treatment

Locations

161 sites in 36 countries. Site status is shown where the registry gives one.

  • AZ Kidney Dise and Hypertension Ctr

    Glendale, Arizona · Active not recruiting

  • Kaiser Permanente

    San Diego, California · Active not recruiting

  • North America Research Institute

    San Dimas, California · Active not recruiting

  • University of Colorado Anschutz

    Aurora, Colorado · Active not recruiting

  • Nephrology Associates PA

    Newark, Delaware · Withdrawn

  • CaRe Research

    Chubbuck, Idaho · Active not recruiting

  • Nep Assoc of Northern Illinois

    Hinsdale, Illinois · Active not recruiting

  • Johns Hopkins Hospital

    Baltimore, Maryland · Active not recruiting

  • Brigham and Womens Hosp Harvard Med School

    Boston, Massachusetts · Completed

  • Mayo Clinic Rochester

    Rochester, Minnesota · Active not recruiting

  • Clin Rsrch Consult a JCCT Company

    Kansas City, Missouri · Completed

  • DaVita Clinical Research

    Las Vegas, Nevada · Active not recruiting

  • New Jersey Kidney Care

    Jersey City, New Jersey · Active not recruiting

  • Col Uni Med Center New York Presby

    New York, New York · Recruiting

  • Dallas Renal Group

    Dallas, Texas · Active not recruiting

  • Prolato Clinical Research Center

    Houston, Texas · Withdrawn

  • Novartis Investigative Site

    CABA, Argentina · Active not recruiting

  • Novartis Investigative Site

    CABA, Argentina · Active not recruiting

  • Novartis Investigative Site

    Santa Fe, Argentina · Active not recruiting

  • Novartis Investigative Site

    Córdoba, Córdoba Province, Argentina · Active not recruiting

  • Novartis Investigative Site

    Córdoba, Córdoba Province, Argentina · Active not recruiting

  • Novartis Investigative Site

    Woolloongabba, Queensland, Australia · Active not recruiting

  • Novartis Investigative Site

    Adelaide, South Australia, Australia · Active not recruiting

  • Novartis Investigative Site

    Parkville, Victoria, Australia · Active not recruiting

  • Novartis Investigative Site

    Edegem, Belgium · Active not recruiting

  • Novartis Investigative Site

    Leuven, Belgium · Active not recruiting

  • Novartis Investigative Site

    Roeselare, West Vlaanderen, Belgium · Active not recruiting

  • Novartis Investigative Site

    Belo Horizonte, Minas Gerais, Brazil · Active not recruiting

  • Novartis Investigative Site

    Curitiba, Paraná, Brazil · Active not recruiting

  • Novartis Investigative Site

    Porto Alegre, Rio Grande do Sul, Brazil · Active not recruiting

  • Novartis Investigative Site

    São José do Rio Preto, São Paulo, Brazil · Active not recruiting

  • Novartis Investigative Site

    São Paulo, São Paulo, Brazil · Active not recruiting

  • Novartis Investigative Site

    São Paulo, São Paulo, Brazil · Active not recruiting

  • Novartis Investigative Site

    Oshawa, Ontario, Canada · Withdrawn

  • Novartis Investigative Site

    Temuco, Chile · Active not recruiting

  • Novartis Investigative Site

    Beijing, China · Active not recruiting

  • Novartis Investigative Site

    Guangzhou, China · Active not recruiting

  • Novartis Investigative Site

    Ningbo, China · Active not recruiting

  • Novartis Investigative Site

    Qingdao, China · Active not recruiting

  • Novartis Investigative Site

    Shanghai, China · Active not recruiting

Showing 40 of 161 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.